Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673650 | 0.87 | KMT2A (0.73) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL9341104 | 0.86 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL31658991 | 0.86 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL31204437 | 0.85 | KMT2A (0.66) | KMT2ASMN1; SMN2EPHX2MEN1HTT | |
| Hydrochloric Acid SCHEMBL27924635 | 0.85 | KMT2A (0.71) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL7874821 | 0.85 | ALDH1A1 (0.62) | KMT2ASMN1; SMN2EPHX2MEN1HTT | |
| SCHEMBL1219736 | 0.85 | KMT2A (0.66) | KMT2ASMN1; SMN2EPHX2MEN1HTT | |
| SCHEMBL28244458 | 0.85 | KMT2A (0.65) | KMT2ASMN1; SMN2EPHX2MEN1HTT | |
| SCHEMBL10086056 | 0.84 | ALDH1A1 (0.60) | KMT2ASMN1; SMN2EPHX2MEN1HTT | |
| Hydrochloric Acid SCHEMBL27432340 | 0.84 | KMT2A (0.64) | KMT2ASMN1; SMN2EPHX2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526091-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TaiMed Biologics, Inc. (TW) | 2012-11-28 | — | — | EP | claimed |
| WO-2011088549-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA INC. (CA) | 2011-07-28 | — | — | WO | claimed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | claimed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | claimed |
| WO-2025136134-A1 | DIMETHYLBIPHENYL COVALENT PD-L1/PD-1 INTERACTION INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAID INHIBITOR AND THE USE THEREOF | Uniwersytet Jagielloński (PL) | 2025-06-26 | — | — | WO | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| WO-2020237374-A1 | PICOLINIC ACID DERIVATIVES AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH ELEVATED CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2020-12-03 | — | — | WO | disclosed |
| CN-109641854-A | Integration stress access regulator | 卡里科生命科学有限责任公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-2964644-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138484-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014120658-A1 | FUSED MULTICYCLIC 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE DERIVATIVES AND THEIR USE AS BETA-SECRETASE INHIBITORS | AMGEN INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-8664248-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | TAIMED BIOLOGICS, INC. (TW) | 2014-03-04 | — | — | US | disclosed |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA, INC. (CA) | 2012-12-27 | — | — | US | disclosed |
| US-8283366-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | AMBRILIA BIOPHARMA, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
| EP-0060144-A2 | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | KMT2A 4239/4885SMN1; SMN2 3911/4885EPHX2 1896/4885 |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | KMT2A 2997/4885SMN1; SMN2 3521/4885EPHX2 1095/4885 |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | KMT2A 1953/4885SMN1; SMN2 3503/4885EPHX2 596/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | KMT2A 4239/4885SMN1; SMN2 3911/4885EPHX2 1896/4885 |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | KMT2A 2997/4885SMN1; SMN2 3521/4885EPHX2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.